Delos Capital
  • Delos
  • Team
  • Connects
  • Companies
  • News
  • Contact
Select Page

Clover’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5

by Admin | Aug 30, 2022 | Portfolio News

— 12 to 61-fold increase in neutralizing antibodies against BA.5 among participants receiving SCB-2019 (CpG 1018/Alum) as a homologous third dose or with a history of prior SARS-CoV-2 infection — — BA.5 neutralizing antibody levels were approximately...

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors

by Admin | Aug 29, 2022 | Portfolio News

SAN DIEGO, Aug. 23, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the first patient has been dosed in the phase 1 clinical study...

Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine

by Admin | Aug 29, 2022 | Portfolio News

— SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years) — — Favorable tolerability and safety profile in adolescents,...

Eccogene Announces US IND Approval for THRβ agonist ECC4703

by Admin | Aug 2, 2022 | Portfolio News

Shanghai/August.1st, 2022 — Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate...

TRUVIC Announces 510(k) Clearance for the Prodigy™ Thrombectomy System

by Admin | Apr 12, 2022 | Portfolio News

First regulatory milestone as part of a strategy to advance patient care April 11, 2022 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Truvic Medical, Inc., a wholly owned subsidiary of Imperative Care, Inc., today announced that...

Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe

by Admin | Jan 14, 2022 | Portfolio News

Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royaltiesADVANZ gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom, Switzerland, and NorwayCefepime/enmetazobactam has...
« Older Entries
Next Entries »
  • © 2019 Delos Capital Partners / Delos Life Science
  • Privacy Policy
  • Terms of Use
  • Contact